LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$14.05
1.08 (8.33%)
▲
5d:
+12.49%
30d:
-5.64%
90d:
-32.48%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LYEL shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: LYEL shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $14.05, which is considered fair relative to its 30-day fair value range of $11.99 to $15.35.
Technical Outlook: Technically, LYEL is in a strong downtrend. The price is approaching resistance at $14.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: LYEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.17 (+164.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LYEL is in a strong downtrend. The price is approaching resistance at $14.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: LYEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.17 (+164.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.99 -
$15.35
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
93.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.3%)
- BULLISH: Trading 164.5% below Wall St target ($37.17)
Trading Range Analysis
30-Day Trading Range
$11.99 -
$15.35
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.03
(14.4%)
Support & Resistance Levels
Support Level
$11.47
Resistance Level
$14.21
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$37.17
(+164.5%)
Revenue Growth (YoY)
-71.4%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:48 PM
Data refreshes hourly during market hours. Next update: 11:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$34 | 67 BUY |
